Venture capital activity rises for biotech, AI, and Gen Alpha founders

Several significant funding developments and trends are emerging in the technology and biotech sectors. Ascensia has led a $36 million Series B funding round for Sava, a company aiming to replace fingerstick glucose testing. Meanwhile, Isomorphic Labs, a spinout from DeepMind, is reportedly eyeing a $40 billion valuation following a $2.1 billion investment round.

In the infrastructure and hardware space, SpaceX is reportedly seeking $40 billion, led by Apollo, to purchase Nvidia chips. Additionally, OllyGarden has raised $4 million with backing from Datadog, Grafana Labs, and Dash0 to address telemetry waste.

On the human capital front, venture capitalists are observing the rise of Generation Alpha founders. Investors note that while these young entrepreneurs demonstrate significant hustle and an innate ability to use AI tools, there are concerns regarding potential cognitive offloading and the impact of AI on critical thinking skills.